Ratings by BMO Capital (Evan David Seigerman)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 4/18/2024 | Eli Lilly | LLY | Maintain | Outperform (N/A) |
|
Details | ||
| 4/12/2024 | Amgen | AMGN | Maintain | Outperform (N/A) |
|
Details | ||
| 4/12/2024 | Eli Lilly | LLY | Maintain | Outperform (N/A) |
|
Details | ||
| 4/12/2024 | Novo Nordisk | NVO | New Coverage | Outperform (N/A) |
124.93 (122.71) |
-1.78% | Details | |
| 4/2/2024 | Disc Medicine | IRON | Maintain | Outperform (N/A) |
|
Details | ||
| 3/15/2024 | Gilead Sciences | GILD | Maintain | Outperform (N/A) |
|
Details | ||
| 2/29/2024 | Disc Medicine | IRON | Maintain | Outperform (N/A) |
|
Details | ||
| 2/14/2024 | Biogen | BIIB | Maintain | Outperform (N/A) |
|
Details | ||
| 2/14/2024 | Incyte | INCY | Maintain | Market Perform (N/A) |
|
Details | ||
| 2/7/2024 | Eli Lilly | LLY | Maintain | Outperform (N/A) |
|
Details | ||
| 2/5/2024 | Regeneron Pharma | REGN | Maintain | Outperform (N/A) |
|
Details | ||
| 12/19/2023 | Amgen | AMGN | Upgrade | Outperform (Market Perform) |
275.45 (268.93) |
-2.37% | Details | |
| 12/11/2023 | Eli Lilly | LLY | Maintain | Outperform (N/A) |
|
Details | ||
| 11/20/2023 | Bristol-Myers Squibb Co. | BMY | Maintain | Market Perform (N/A) |
|
Details | ||
| 11/10/2023 | Neurocrine Bio. | NBIX | Maintain | Market Perform (N/A) |
|
Details | ||
| 11/9/2023 | Biogen | BIIB | Maintain | Outperform (N/A) |
|
Details | ||
| 11/7/2023 | Vertex | VRTX | Maintain | Outperform (N/A) |
|
Details | ||
| 10/27/2023 | Bristol-Myers Squibb Co. | BMY | Downgrade | Market Perform (Outperform) |
56.61 (48.93) |
-13.57% | Details | |
| 10/27/2023 | Merck | MRK | Upgrade | Outperform (Market Perform) |
103.63 (125.78) |
21.37% | Details | |
| 10/16/2023 | Pfizer | PFE | Maintain | Outperform (N/A) |
|
Details | ||
| 10/6/2023 | Mirati Therapeutics | MRTX | Maintain | Market Perform (N/A) |
|
Details | ||
| 9/12/2023 | Neurocrine Bio. | NBIX | Maintain | Market Perform (N/A) |
|
Details | ||
| 8/21/2023 | Regeneron Pharma | REGN | Maintain | Outperform (N/A) |
|
Details | ||
| 8/8/2023 | Biogen | BIIB | Maintain | Outperform (N/A) |
|
Details | ||
| 8/4/2023 | Amgen | AMGN | Maintain | Market Perform (N/A) |
|
Details | ||
| 8/2/2023 | Neurocrine Bio. | NBIX | Maintain | Market Perform (N/A) |
|
Details | ||
| 8/2/2023 | Incyte | INCY | Maintain | Market Perform (N/A) |
|
Details | ||
| 8/2/2023 | Pfizer | PFE | Maintain | Outperform (N/A) |
|
Details | ||
| 8/2/2023 | Vertex | VRTX | Maintain | Outperform (N/A) |
|
Details | ||
| 7/28/2023 | Bristol-Myers Squibb Co. | BMY | Maintain | Outperform (N/A) |
|
Details | ||
| 7/26/2023 | Biogen | BIIB | Maintain | Outperform (N/A) |
|
Details | ||
| 7/6/2023 | Neurocrine Bio. | NBIX | Upgrade | Market Perform (Underperform) |
94.48 (132.00) |
39.71% | Details | |
| 6/12/2023 | Disc Medicine | IRON | Maintain | Outperform (N/A) |
|
Details | ||
| 5/25/2023 | Mirati Therapeutics | MRTX | Maintain | Market Perform (N/A) |
|
Details | ||
| 5/16/2023 | Gilead Sciences | GILD | Upgrade | Outperform (Market Perform) |
78.17 (66.76) |
-14.6% | Details | |
| 5/15/2023 | Candel Therapeutics Inc. | CADL | Maintain | Outperform (N/A) |
|
Details | ||
| 5/4/2023 | Eli Lilly | LLY | Maintain | Outperform (N/A) |
|
Details | ||
| 5/3/2023 | Incyte | INCY | Maintain | Market Perform (N/A) |
|
Details | ||
| 3/24/2023 | Regeneron Pharma | REGN | Maintain | Outperform (N/A) |
|
Details | ||
| 3/23/2023 | Disc Medicine | IRON | New Coverage | Outperform (N/A) |
22.24 (28.69) |
29% | Details | |
| 3/14/2023 | Regeneron Pharma | REGN | Maintain | Outperform (N/A) |
|
Details | ||
| 3/1/2023 | Mirati Therapeutics | MRTX | Maintain | Market Perform (N/A) |
|
Details | ||
| 2/3/2023 | Merck | MRK | Maintain | Market Perform (N/A) |
|
Details | ||
| 2/1/2023 | Pfizer | PFE | Maintain | Outperform (N/A) |
|
Details | ||
| 2/1/2023 | Amgen | AMGN | Maintain | Market Perform (N/A) |
|
Details | ||
| 12/20/2022 | Gilead Sciences | GILD | Maintain | Market Perform (N/A) |
|
Details | ||
| 12/20/2022 | Bristol-Myers Squibb Co. | BMY | Maintain | Outperform (N/A) |
|
Details | ||
| 12/20/2022 | Amgen | AMGN | Maintain | Market Perform (N/A) |
|
Details | ||
| 12/14/2022 | Eli Lilly | LLY | Maintain | Outperform (N/A) |
|
Details | ||
| 12/8/2022 | Mirati Therapeutics | MRTX | Downgrade | Market Perform (Outperform) |
71.52 (58.70) |
-17.93% | Details | |
| 11/4/2022 | Amgen | AMGN | Maintain | Market Perform (N/A) |
|
Details | ||
| 11/2/2022 | Neurocrine Bio. | NBIX | Maintain | Underperform (N/A) |
|
Details | ||
| 10/28/2022 | Merck | MRK | Maintain | Market Perform (N/A) |
|
Details | ||
| 10/21/2022 | Pfizer | PFE | Maintain | Outperform (N/A) |
|
Details | ||
| 10/21/2022 | Bristol-Myers Squibb Co. | BMY | Maintain | Outperform (N/A) |
|
Details | ||
| 10/21/2022 | Regeneron Pharma | REGN | Maintain | Outperform (N/A) |
|
Details | ||
| 9/28/2022 | Biogen | BIIB | Upgrade | Outperform (Market Perform) |
195.75 (194.38) |
-0.7% | Details | |
| 9/22/2022 | Pfizer | PFE | Maintain | Outperform (N/A) |
|
Details | ||
| 9/12/2022 | Bristol-Myers Squibb Co. | BMY | Maintain | Outperform (N/A) |
|
Details | ||
| 9/8/2022 | Regeneron Pharma | REGN | Maintain | Outperform (N/A) |
|
Details | ||
| 9/6/2022 | Eli Lilly | LLY | Maintain | Outperform (N/A) |
|
Details | ||
| 8/3/2022 | Gilead Sciences | GILD | Maintain | Market Perform (Market Perform) |
|
Details | ||
| 8/2/2022 | Incyte | INCY | Maintain | Market Perform (Market Perform) |
|
Details | ||
| 7/20/2022 | Biogen | BIIB | Maintain | Market Perform (Market Perform) |
|
Details | ||
| 7/19/2022 | Incyte | INCY | Maintain | Market Perform (Market Perform) |
|
Details | ||
| 7/11/2022 | Vertex | VRTX | Maintain | Outperform (Outperform) |
|
Details | ||
| 7/5/2022 | Vertex | VRTX | Maintain | Outperform (Outperform) |
|
Details | ||
| 6/24/2022 | Regeneron Pharma | REGN | Maintain | Outperform (Outperform) |
|
Details | ||
| 6/7/2022 | Mirati Therapeutics | MRTX | Maintain | Outperform (Outperform) |
|
Details | ||
| 6/6/2022 | Gilead Sciences | GILD | Maintain | Market Perform (Market Perform) |
|
Details | ||
| 5/6/2022 | Eli Lilly | LLY | Maintain | Outperform (N/A) |
|
Details | ||
| 5/4/2022 | Neurocrine Bio. | NBIX | Maintain | Underperform (Underperform) |
|
Details | ||
| 5/4/2022 | Regeneron Pharma | REGN | Maintain | Outperform (Outperform) |
|
Details | ||
| 5/3/2022 | Biogen | BIIB | Maintain | Market Perform (Market Perform) |
|
Details | ||
| 5/2/2022 | Bristol-Myers Squibb Co. | BMY | Maintain | Outperform (N/A) |
|
Details | ||
| 4/29/2022 | Bristol-Myers Squibb Co. | BMY | Maintain | Outperform (Outperform) |
|
Details | ||
| 4/28/2022 | Gilead Sciences | GILD | Maintain | Market Perform (Market Perform) |
|
Details | ||
| 4/28/2022 | Eli Lilly | LLY | Maintain | Outperform (Outperform) |
|
Details | ||
| 4/27/2022 | Amgen | AMGN | Maintain | Market Perform (Market Perform) |
|
Details | ||
| 4/19/2022 | Regeneron Pharma | REGN | Maintain | Outperform (Outperform) |
|
Details | ||
| 4/7/2022 | Pfizer | PFE | Maintain | Outperform (Outperform) |
|
Details | ||
| 4/5/2022 | Merck | MRK | Maintain | Outperform (Outperform) |
|
Details | ||
| 3/31/2022 | Candel Therapeutics Inc. | CADL | Maintain | Outperform (N/A) |
|
Details | ||
| 3/30/2022 | Amgen | AMGN | Maintain | Market Perform (Market Perform) |
|
Details | ||
| 3/30/2022 | Bristol-Myers Squibb Co. | BMY | Maintain | Outperform (N/A) |
|
Details | ||
| 3/29/2022 | Regeneron Pharma | REGN | Maintain | Outperform (Outperform) |
|
Details | ||
| 3/23/2022 | Pfizer | PFE | Maintain | Outperform (Outperform) |
|
Details | ||
| 3/22/2022 | Vertex | VRTX | Maintain | Outperform (Outperform) |
|
Details | ||
| 3/15/2022 | Biogen | BIIB | Maintain | Outperform (Outperform) |
|
Details | ||
| 3/14/2022 | Bristol-Myers Squibb Co. | BMY | Maintain | Outperform (Outperform) |
|
Details | ||
| 3/7/2022 | Biogen | BIIB | Maintain | Market Perform (Market Perform) |
|
Details | ||
| 3/7/2022 | Gilead Sciences | GILD | Maintain | Market Perform (Market Perform) |
|
Details | ||
| 3/4/2022 | Gilead Sciences | GILD | Maintain | Market Perform (Market Perform) |
|
Details | ||
| 3/1/2022 | Pfizer | PFE | Maintain | Outperform (Outperform) |
|
Details | ||
| 3/1/2022 | Mirati Therapeutics | MRTX | Maintain | Outperform (Outperform) |
|
Details | ||
| 2/28/2022 | Gilead Sciences | GILD | Downgrade | Market Perform (Outperform) |
60.61 (78.17) |
28.97% | Details | |
| 2/16/2022 | Biogen | BIIB | Maintain | Market Perform (Market Perform) |
|
Details | ||
| 2/16/2022 | Gilead Sciences | GILD | Maintain | Outperform (Outperform) |
|
Details | ||
| 2/15/2022 | Amgen | AMGN | Maintain | Market Perform (Market Perform) |
|
Details | ||
| 2/14/2022 | Neurocrine Bio. | NBIX | Maintain | Underperform (N/A) |
|
Details | ||
| 2/11/2022 | Neurocrine Bio. | NBIX | Maintain | Underperform (Underperform) |
|
Details | ||
| 2/11/2022 | Regeneron Pharma | REGN | Maintain | Outperform (Outperform) |
|
Details | ||
| 2/11/2022 | Neurocrine Bio. | NBIX | Maintain | Outperform (Outperform) |
|
Details | ||
| 2/8/2022 | Amgen | AMGN | Maintain | Market Perform (Market Perform) |
|
Details | ||
| 2/8/2022 | Incyte | INCY | Maintain | Market Perform (Market Perform) |
|
Details | ||
| 2/8/2022 | Pfizer | PFE | Maintain | Outperform (Outperform) |
|
Details | ||
| 2/7/2022 | Bristol-Myers Squibb Co. | BMY | Maintain | Outperform (N/A) |
|
Details | ||
| 2/4/2022 | Regeneron Pharma | REGN | Maintain | Outperform (Outperform) |
|
Details | ||
| 2/4/2022 | Bristol-Myers Squibb Co. | BMY | Maintain | Outperform (Outperform) |
|
Details | ||
| 2/4/2022 | Eli Lilly | LLY | Maintain | Outperform (N/A) |
|
Details | ||
| 2/4/2022 | Biogen | BIIB | Downgrade | Market Perform (Outperform) |
220.17 (194.38) |
-11.71% | Details | |
| 2/3/2022 | Biogen | BIIB | Maintain | Outperform (Outperform) |
|
Details | ||
| 2/3/2022 | Merck | MRK | Maintain | Market Perform (Market Perform) |
|
Details | ||
| 2/3/2022 | Eli Lilly | LLY | Maintain | Outperform (Outperform) |
|
Details | ||
| 2/2/2022 | Gilead Sciences | GILD | Maintain | Outperform (Outperform) |
|
Details | ||
| 1/26/2022 | Vertex | VRTX | Maintain | Outperform (Outperform) |
|
Details | ||
| 1/20/2022 | Vertex | VRTX | Upgrade | Outperform (Market Perform) |
231.07 (394.28) |
70.63% | Details | |
| 1/14/2022 | Pfizer | PFE | Maintain | Outperform (Outperform) |
|
Details | ||
| 1/13/2022 | Gilead Sciences | GILD | Maintain | Outperform (Outperform) |
|
Details | ||
| 1/13/2022 | Biogen | BIIB | Maintain | Outperform (N/A) |
|
Details | ||
| 12/16/2021 | Eli Lilly | LLY | Maintain | Outperform (N/A) |
|
Details | ||
| 11/19/2021 | Neurocrine Bio. | NBIX | New Coverage | Underperform (N/A) |
89.60 (132.00) |
47.32% | Details | |
| 11/19/2021 | Vertex | VRTX | New Coverage | Market Perform (N/A) |
188.25 (394.28) |
109.44% | Details | |
| 11/19/2021 | Merck | MRK | New Coverage | Market Perform (N/A) |
82.60 (125.78) |
52.28% | Details | |
| 11/19/2021 | Incyte | INCY | New Coverage | Market Perform (N/A) |
65.02 (52.35) |
-19.49% | Details | |
| 11/19/2021 | Amgen | AMGN | New Coverage | Market Perform (N/A) |
205.82 (268.93) |
30.66% | Details | |
| 11/19/2021 | Regeneron Pharma | REGN | New Coverage | Outperform (N/A) |
641.83 (896.82) |
39.73% | Details | |
| 11/19/2021 | Pfizer | PFE | New Coverage | Outperform (N/A) |
50.87 (26.00) |
-48.89% | Details | |
| 11/19/2021 | Mirati Therapeutics | MRTX | New Coverage | Outperform (N/A) |
138.50 (58.70) |
-57.62% | Details | |
| 11/19/2021 | Eli Lilly | LLY | New Coverage | Outperform (N/A) |
261.18 (726.31) |
178.09% | Details | |
| 11/19/2021 | Candel Therapeutics Inc. | CADL | New Coverage | Outperform (N/A) |
10.60 (5.17) |
-51.23% | Details | |
| 11/19/2021 | Gilead Sciences | GILD | New Coverage | Outperform (N/A) |
67.46 (66.76) |
-1.04% | Details | |
| 11/19/2021 | Bristol-Myers Squibb Co. | BMY | New Coverage | Outperform (N/A) |
59.44 (48.93) |
-17.68% | Details | |
| 11/19/2021 | Biogen | BIIB | New Coverage | Outperform (N/A) |
258.38 (194.38) |
-24.77% | Details |
